Abpro Holdings amends convertible note terms with Yorkville

Published 24/04/2025, 21:32
Abpro Holdings amends convertible note terms with Yorkville

Abpro Holdings, Inc. (NASDAQ:ABP), a biotechnology company specializing in biological products with a market capitalization of $169.66 million, has entered into an amendment with investment firm Yorkville to adjust the terms of a convertible promissory note, as per a recent SEC filing. According to InvestingPro data, the company maintains a GREAT financial health score, though it operates with a moderate level of debt.

On Monday, the company and Yorkville agreed to amend the definition of "Conversion Price" in the note to correct an error. The revised terms set the "Conversion Price" as the lower of $11.50 per share or 94% of the lowest daily volume-weighted average price (VWAP) in the five trading days preceding the conversion date. Additionally, the fixed price may adjust downward based on the VWAP in the three days prior to the 20th trading day following the issuance date, if it is lower than the initial fixed price. The floor price, however, will remain unchanged. Currently trading at $5.57, the stock has shown significant return over the last week, as revealed by InvestingPro analysis.

This convertible note was initially issued on November 13, 2024, with a principal amount of $3 million, from which Abpro Holdings received net proceeds of $2.755 million. The amendment does not change any other terms of the note. The company maintains a healthy current ratio of 3.21, indicating strong ability to meet its short-term obligations.

The convertible note is a financial instrument that allows Yorkville to convert the outstanding balance into shares of Abpro Holdings at the specified conversion price. Such financial agreements are common among companies seeking flexible financing options.

The information in this article is based on a press release statement from Abpro Holdings, Inc. filed with the SEC. Investors are advised to review the full text of the amendment for a complete understanding of its terms.

In other recent news, Abpro Holdings, Inc. has announced it will restate its financial statements for several periods due to an understatement of liabilities, affecting financials for the quarters ending September 30, 2024, and December 31, 2023, as well as the fiscal year ending December 31, 2022. The restatement will increase accrued expenses, total liabilities, and accumulated deficit by approximately $3.3 million for each affected period. Additionally, Abpro Holdings faces a potential delisting from Nasdaq due to non-compliance with the minimum bid price requirement, as its stock has been below the $1.00 minimum for 30 consecutive business days. The company has until September 29, 2025, to regain compliance. Furthermore, Abpro Holdings has approved a significant issuance of common stock to Yorkville, which may exceed 20% of the company’s issued and outstanding shares. This decision was made following a special meeting of stockholders, where the proposal received overwhelming support. The issuance could potentially dilute current shareholders’ equity, but it reflects stockholders’ approval of the company’s strategic direction. These developments highlight ongoing financial and strategic adjustments at Abpro Holdings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.